Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b2 (B.1.1.529.1)
- Development stage
- Approved
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**BNT162b2 (B.1.1.529.1)** is a variant-adapted formulation of the nucleoside-modified mRNA vaccine encoding the spike protein of the SARS-CoV-2 Omicron subvariant B.1.1.529.1 (BA.1). Developed by BioNTech and Pfizer, it elicits immune responses including neutralizing antibodies against the spike antigen to prevent COVID-19 caused by SARS-CoV-2 infection. Administered intramuscularly in a two-dose primary series or as boosters, it received regulatory approvals and authorizations for active immunization across age groups starting from 6 months, with adaptations for emerging variants to maintain efficacy against severe disease, hospitalization, and variants like Omicron.
- Brand names
- Comirnaty
- Other names
- Pfizer-BioNTech COVID-19 VaccineCOVID-19 mRNA vaccineCOVID19 mRNA vaccineCOVID 19 mRNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on BNT162b2 (B.1.1.529.1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b2 (B.1.1.529.1).